The role of glutaminase in cancer

Increased glutamine metabolism (glutaminolysis) is a hallmark of cancer and is recognised as a key metabolic change in cancer cells. Breast cancer is a heterogeneous disease with different morphological and molecular subtypes and responses to therapy, and breast cancer cells are known to rewire glutamine metabolism to support survival and proliferation. Glutaminase isoenzymes (GLS and GLS2) are key enzymes for glutamine metabolism. Interestingly, GLS and GLS2 have contrasting functions in tumorigenesis. In this review, we explore the role of glutaminase in cancer, primarily focusing on breast cancer, address the role played by oncogenes and tumour suppressor genes in regulating glutaminase, and discuss current therapeutic approaches to targeting glutaminase.

[1]  G. Mælandsmo,et al.  Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer , 2019, Breast Cancer Research.

[2]  A. Fan,et al.  The ‘Achilles Heel’ of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy , 2019, Kidney cancer.

[3]  Shaohe Wang,et al.  Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway , 2018, EBioMedicine.

[4]  T. Tsukamoto,et al.  Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase. , 2018, Journal of medicinal chemistry.

[5]  J. Matés,et al.  Glutaminase isoenzymes in the metabolic therapy of cancer. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[6]  M. P. Pinheiro,et al.  N-terminal phosphorylation of glutaminase C decreases its enzymatic activity and cancer cell migration. , 2018, Biochimie.

[7]  M. Losso,et al.  The Human SLC1A5 (ASCT2) Amino Acid Transporter: From Function to Structure and Role in Cell Biology , 2018, Front. Cell Dev. Biol..

[8]  Bentong Yu,et al.  Phosphorylation of glutaminase by PKCε is essential for its enzymatic activity and critically contributes to tumorigenesis , 2018, Cell Research.

[9]  William P. Katt,et al.  Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism , 2018, The Journal of Biological Chemistry.

[10]  I. Ellis,et al.  Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations , 2018, Histopathology.

[11]  I. Ellis,et al.  MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer , 2017, British Journal of Cancer.

[12]  Bin Xu,et al.  miR-137 inhibits glutamine catabolism and growth of malignant melanoma by targeting glutaminase. , 2018, Biochemical and biophysical research communications.

[13]  G. Qing,et al.  Oncogenic MYC Activates a Feedforward Regulatory Loop Promoting Essential Amino Acid Metabolism and Tumorigenesis. , 2017, Cell reports.

[14]  J. Pouysségur,et al.  The Central Role of Amino Acids in Cancer Redox Homeostasis: Vulnerability Points of the Cancer Redox Code , 2017, Front. Oncol..

[15]  D. Wiederschain,et al.  Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition , 2017, PloS one.

[16]  D. Meynial-Denis.  Glutamine : Biochemistry, Physiology, and Clinical Applications , 2017 .

[17]  H. Lee,et al.  Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes , 2017, Virchows Archiv.

[18]  William P. Katt,et al.  A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis. , 2017, Future medicinal chemistry.

[19]  P. Sonveaux,et al.  Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism , 2016, Oncogene.

[20]  D. Hong,et al.  Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC , 2016, Cell Death & Disease.

[21]  J. Velez,et al.  Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes , 2016, Oncotarget.

[22]  B. C. Low,et al.  Structural basis for exploring the allosteric inhibition of human kidney type glutaminase , 2016, Oncotarget.

[23]  J. Erickson,et al.  The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy , 2016, Nature Communications.

[24]  A. Le,et al.  Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold , 2016, ACS medicinal chemistry letters.

[25]  J. Locasale,et al.  The Warburg Effect: How Does it Benefit Cancer Cells? , 2016, Trends in biochemical sciences.

[26]  G. Bhanot,et al.  Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis , 2016, eLife.

[27]  W. Ritchie,et al.  ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer , 2015, Oncogene.

[28]  Chunxiao Zhou,et al.  Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer. , 2016, American journal of translational research.

[29]  Yitao Ding,et al.  Expression of glutaminase 1 gene in breast cancer and its clinical significance in neoadjuvant chemotherapy , 2016 .

[30]  Y. Bhutia,et al.  Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. , 2015, Cancer research.

[31]  O. Fiehn,et al.  Glutamate enrichment as new diagnostic opportunity in breast cancer , 2015, International journal of cancer.

[32]  Yitao Ding,et al.  Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma , 2015, Oncotarget.

[33]  R. Deberardinis,et al.  Metabolic pathways promoting cancer cell survival and growth , 2015, Nature Cell Biology.

[34]  Guojun Wu,et al.  Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer. , 2015, Biochemical and biophysical research communications.

[35]  J. Blenis,et al.  The mTORC1/S6K1 Pathway Regulates Glutamine Metabolism through the eIF4B-Dependent Control of c-Myc Translation , 2014, Current Biology.

[36]  Y. Chao,et al.  Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells , 2014, Oncotarget.

[37]  Wenwei Hu,et al.  Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma , 2014, Oncotarget.

[38]  N. Sang,et al.  ErbB2 Activation Upregulates Glutaminase 1 Expression Which Promotes Breast Cancer Cell Proliferation , 2014, Journal of cellular biochemistry.

[39]  Tao Zhang,et al.  Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. , 2014, International journal of clinical and experimental pathology.

[40]  Jennifer B Dennison,et al.  Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer , 2014, Molecular Cancer Therapeutics.

[41]  Oliver Fiehn,et al.  Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. , 2013, Journal of proteomics.

[42]  R. Deberardinis,et al.  Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells , 2013, Journal of Molecular Medicine.

[43]  K. Vousden,et al.  Metabolic Regulation by p53 Family Members , 2013, Cell metabolism.

[44]  Jan Albrecht,et al.  Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells , 2013, Tumor Biology.

[45]  Ralph J DeBerardinis,et al.  Glutamine and cancer: cell biology, physiology, and clinical opportunities. , 2013, The Journal of clinical investigation.

[46]  W. Jung,et al.  Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. , 2013, Endocrine-related cancer.

[47]  J. Matés,et al.  Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. , 2013, Current molecular medicine.

[48]  J. Erickson,et al.  Rho GTPases and their roles in cancer metabolism. , 2013, Trends in molecular medicine.

[49]  K. Bachman,et al.  Analysis of glutamine dependency in non-small cell lung cancer , 2012, Cancer biology & therapy.

[50]  E. Gottlieb,et al.  Glutaminolysis activates Rag-mTORC1 signaling. , 2012, Molecular cell.

[51]  William P. Katt,et al.  Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation , 2012, Molecular Cancer Therapeutics.

[52]  A. Cassago,et al.  Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism , 2012, Proceedings of the National Academy of Sciences.

[53]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[54]  J. Chi,et al.  Glutamine Synthetase Is a Genetic Determinant of Cell Type–Specific Glutamine Independence in Breast Epithelia , 2011, PLoS genetics.

[55]  C. Dang,et al.  Therapeutic targeting of cancer cell metabolism , 2011, Journal of Molecular Medicine.

[56]  G. Riggins,et al.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.

[57]  C. Dang,et al.  Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. , 2010, Cancer cell.

[58]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[59]  A. Levine,et al.  Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function , 2010, Proceedings of the National Academy of Sciences.

[60]  S. Sugano,et al.  Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species , 2010, Proceedings of the National Academy of Sciences.

[61]  M. Szeliga,et al.  Glutamine in neoplastic cells: Focus on the expression and roles of glutaminases , 2009, Neurochemistry International.

[62]  Jennifer E. Van Eyk,et al.  c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2016 .

[63]  Jeffrey P. MacKeigan,et al.  Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy , 2009, Cell.

[64]  Anthony Mancuso,et al.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction , 2008, Proceedings of the National Academy of Sciences.

[65]  Ralph J Deberardinis,et al.  Brick by brick: metabolism and tumor cell growth. , 2008, Current opinion in genetics & development.

[66]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.

[67]  N. Curthoys,et al.  Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). , 2007, The Biochemical journal.

[68]  B. Fuchs,et al.  Stressing out over survival: glutamine as an apoptotic modulator. , 2006, The Journal of surgical research.

[69]  J. Márquez,et al.  Identification of two human glutaminase loci and tissue-specific expression of the two related genes , 2000, Mammalian Genome.

[70]  W. Souba,et al.  Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. , 1999, Physiological genomics.

[71]  H. Eagle.  Metabolic Controls in Cultured Mammalian Cells , 1965, Science.